Add Formweb to your mobile device
System Formulary Update
Class Standardization: Protease Inhibitors (PIs)
January 1, 1970
Situation
The protease inhibitors class review standardization was approved at the System Pharmacy and Therapeutics Committee meeting in April 2024.
Background
The following therapeutic interchange was reviewed: atazanavir capsules, atazanavir oral powder, atazanavir-cobicistat tablets, darunavir oral suspension, darunavir tablets, darunavir-cobicistat tablets, darunavir-cobicistat-emtricitabine-tenofovir alafenamide tablets, fosemprenavir tablets, lopinavir-ritonavir oral solution, lopinavir-ritonavir tablets, nelfinavir tablets, ritonavir oral powder, ritonavir oral solution, ritonavir tablets, tipranavir capsules, and tipranavir oral solution
Assessment/ Recommendations:
System P&T voted to include the following products on the UNC Health System Drug Formulary:
- Darunavir 600 mg tablet
- Darunavir 800 mg tablet
- Ritonavir 100 mg tablet
- Lopinavir-ritonavir 400 mg-100 mg/5 mL oral solution
Therapeutic interchanges will also be included for the following:
| Non-Formulary Order |
Formulary Equivalent Order |
|
Darunavir 800 mg/cobicistat 150 mg (Prezcobix®) Combination tablet |
Equivalent dose darunavir tablet + cobicistat tablet |
|
Darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/TAF 10 mg (Symtuza®) Combination tablet |
Equivalent dose darunavir tablet + cobicistat tablet + emtricitabine/TAF Combination tablet |
Formulary/Epic changes will Go-Live on Tuesday, June 18, 2024.